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Edited by Beat ImhofAbstract The aim of this study was to investigate the role of
adiponectin (APN) in a mouse model of laser induced choroidal
neovascularization (CNV). We have shown by immunohisto-
chemistry that the expression of APN, adiponectin receptor 1,
adiponectin receptor 2 and T cadherin gradually increased from
day 1 to day 7 post-laser in laser treated mice compared to con-
trols. Recombinant APN (rAPN) was injected intraperitoneally
(i.p., 25 lg/mouse) or intravitreally (2 lg/eye) in lasered mice.
Another set of lasered mice received APN peptide via i.p.
(75 lg/mouse) or intravitreal (30 lg/eye) route. Control mice re-
ceived a similar treatment with PBS, control protein or control
peptide after laser treatment. We found that in the i.p. and intra-
vitreal injection of rAPN resulted in 78% and 68% inhibition
respectively in the size of CNV complex compared to control
mice. Similar results were observed when APN peptide was in-
jected intravitreally or i.p. Treatment with rAPN or the peptide
resulted in decreased levels of vascular endothelial growth factor.
Thus, APN inhibited choroidal angiogenesis and may have ther-
apeutic implications in the treatment of wet age related macular
degeneration.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Adiponectin (APN) is an adipocyte-speciﬁc plasma protein,
secreted by adipose cells and mimics many metabolic actions
of insulin [1]. APN shares sequence homology with a family
of proteins showing a modular design containing a C-terminal
complement factor C1q-like globular domain and the C-termi-
nal globular domain of APN is also strikingly similar to that of
tumor necrosis factor-alpha (TNF-a) [1,2]. A full cDNA
encoding the adiponectin receptor 1 (AdipoR1) and adiponec-Abbreviations: CNV, choroidal neovascularization; AMD, age related
macular degeneration; APN, adiponectin; VEGF, vascular endothelial
growth factor; FGF, ﬁbroblast growth factor; rAPN, recombinant
adiponectin; AdipoR1, adiponectin receptor 1; AdipoR2, adiponectin
receptor 2; Tcad, T cadherin
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doi:10.1016/j.febslet.2007.04.024tin receptor 2 (AdipoR2) has been isolated from the mouse as
well as from the humans [3]. APN acts via two receptor iso-
forms, AdipoR1 and AdipoR2 [3]. AdipoR1 and AdipoR2
contain seven transmembrane domains, but are structurally
and functionally diﬀerent from G protein-coupled receptors
[4–10].
Plasma APN concentrations were signiﬁcantly lower in pa-
tients with obesity, type II diabetes and coronary artery disease
[11]. The decreased plasma APN concentration in diabetes has
been reported to be an indicator of macroangiopathy [12,13].
APN may be an important link between insulin resistance, type
II diabetes and atherosclerosis and thus could be an important
target for future diabetes therapy [14,15]. There are few reports
regarding the role of APN in angiogenesis and one report sug-
gested that APN is an anti-angiogenic protein [16,17]. The role
of APN in the eye has not been studied. The present study was
designed to investigate the role of APN in choroidal angiogen-
esis by using rodent model of laser-induced choroidal neovas-
cularization (CNV) [18–24]. Age related macular degeneration
(AMD) is the leading cause of blindness in the Western world
in individuals over the age of 55 years. Our results presented
here suggest that APN and APN receptors are present in the
eye and the recombinant adiponectin (rAPN) or peptide gener-
ated from APN may have therapeutic potential in the treat-
ment of CNV associated with wet AMD as well as in other
angiogenesis-dependent diseases like cancer, atherosclerosis
and obesity.2. Methods
2.1. Materials
C57BL/6 mice 4–6 weeks old were purchased from the Jackson Lab-
oratory (Bar Harbor, ME). This study was approved by the Institu-
tional Animal Care and Use Committee (IACUC), University of
Arkansas for Medical Sciences (UAMS), Little Rock, AR.
2.2. Immunohistochemistry
The following were used for the lasered mice: goat polyclonal anti-
adiponectin antibody (R&D Systems, Minneapolis, MN) in a 1:200
dilution; rabbit anti-adiponectin receptor 1serum (Phoenix Pharma-
ceuticals, Belmont, CA) – 1:1600; rabbit anti-adiponectin receptor 2
serum (Phoenix Pharmaceuticals) – 1:2000; rabbit anti-T-cadherin
(Santa Cruz, CA) – 1:300; secondary rabbit anti-goat IgG (H+L) FITC
conjugate (Invitrogen, San Francisco, CA) and Alexa Fluor goat
anti-rabbit IgG (H+L) (Invitrogen) – in a 1:400 dilution [18,19].
Semiquantitative scaling of positive signal was performed. The inten-
sity of ﬂuorescence was graded from 0 to 3 (0 – no staining; 1 – faint;ation of European Biochemical Societies.
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Fig. 1. Semiquantitative scoring of immunohistochemical staining for
APN, AdipoR1, AdipoR2 and Tcad during development of CNV
(M ± S.E.). In ﬁgures: 1d – 1 day; 3d – 3 days, 5d – 5 days and 7d – 7
days after laser injury. Data were subjected to ANOVA/MANOVA
analysis. *P < 0.05; **P < 0.01; ***P < 0.001. All values compared to
control. n = 13–19 per group.
1978 P.S. Bora et al. / FEBS Letters 581 (2007) 1977–19822 – moderate; 3 – intense). Please see supplementary material for more
information.
2.3. RT-PCR analysis
Ten laser spots were placed in each eye of C57BL/6 mice as described
below. Animals from rAPN treated and peptide treated groups
(n = 10) were sacriﬁced at days 3 post-laser treatment; RPE-choroidal
tissues harvested from the enucleated eyes were pooled separately for
each group, and total RNA was prepared using SV Total RNA Isola-
tion kit (Promega) [19]. RT-PCR was conducted using the following
primers: b-actin (F, 5 0-GCC ACC AGT TCG CCA TGG ATG A-3 0;
R 5 0-GTC AGG CAG CTC ATA GCT CTT C-3 0); VEGF (F,
5 0-GCGGGCTGCCTCGCAGTC-3 0; R, 5 0-TCACCGCCTTGGCTT-
GTCAC- 3 0). Please see supplementary material for more information.
2.4. Western Blot analysis
RPE-choroidal tissues from rAPN treated and peptide treated
groups (n = 10, at day 3, post-laser treatment) were collected, homog-
enized and solubilized in ice cold PBS (2.0 ml/eye) containing protease
inhibitors, phenylmethylsulfonyl ﬂuoride (1 lg/ml), aprotinin (1 lg/
ml), and EDTA (1 mM). The homogenates were centrifuged at
18,000 · g at 4 C for 30 min [19,25]. Please see supplementary material
for more information.
2.5. Induction of CNV in mice and APN treatment
Animals (C57BL/6 mice) are divided in to following groups, 1,
rAPN treated i.p.; 2, rAPN treated intravitreal; 3, control treated with
PBS i.p.; 4, control treated with b-actin i.p.; 5, control treated with
PBS intravitreal; 6, control treated with b-actin intravitreal. CNV
was induced by laser photocoagulation with the Argon laser (50 lm
spot size; 0.05 s duration; 250 mW) as previously described by us
[18,19,25]. Three laser spots were placed in each eye close to the optic
nerve. In group 1, 5 mice were treated i.p. with 25 lg/mouse of rAPN,
1 day before laser photocoagulation and every day after laser treat-
ment until day 6. In group 2, mice (n = 5) were injected 2 lg (single
injection) (intravitreal) on day 1. Two controls were used for each
group. Controls (n = 5) were injected with b-actin or PBS (either i.p.
or intravitreal). All the experiments were repeated three times. Please
see supplementary material for more information.
2.6. Peptide administration
A region of APN (globular domain) which has no homology with
C1q (complement protein) was selected to synthesize the peptide,
NH2-KDKAVLFTYDQYQEKNVD – COOH. A control peptide,
NH2-FSVGLETRVTVPNVPIRF – COOH was also synthesized from
the same region of APN which has no homology with C1q (synthesized
at Peptide Biochemical Research Inc., Seattle, USA; dissolved in PBS).
In one group, seven i.p. injections of the peptide (75 lg/mouse) were
given, one preceding laser treatment and six following the laser treat-
ment. The second group (n = 5) was photocoagulated on day 0 fol-
lowed by a single 30 lg intravitreal injection. Controls for each
group were given control peptide or PBS injections. All the experi-
ments were repeated three times. Please see supplementary material
for more information.
2.7. Three dimensional (3D) structures
All the molecular modeling calculations were performed using
SYBYL program, package version 7.0 on a Silicon Graphics octane
system with IRIX 6.5 operating system. The structure of the peptide
was built using the ‘build protein’ tool in SYBYL. Total energies of
the various conformations of the polypeptide were calculated, and
the least energy conformer was identiﬁed. The total energy of the low-
est energy conformer for the peptide was calculated to be 43.145 har-
trees. Please see supplementary material for more information.
2.8. Measurement of CNV
Seven days after laser treatment, all animals were perfused with 1 ml
of PBS containing 50 mg/ml ﬂuorescein-labeled dextran (FITC-dex-
tran; average molecular mass, 2 · 106; Sigma–Aldrich) and sacriﬁced.
The eyes were harvested and ﬁxed in 10% phosphate-buﬀered formalin,
and retinal pigment epithelium (RPE)-choroid-scleral ﬂat mounts were
prepared as previously described [18,19]. Please see supplementary
material for more information.2.9. Statistical analysis
Data were subjected to equality of variance F test and ANOVA
using Statistica program. Diﬀerences were considered statistically sig-
niﬁcant with P < 0.05.3. Results
3.1. Expression of APN in mouse choroid
Within the normal eye, weak expression of APN was ob-
served in the choroidal tissue. AdipoR1, AdipoR2 and T cad-
herin (Tcad) staining was also weak in the normal choroidal
tissue (Figs. 1 and S1, please see supplementary data). APN
staining increased in laser injured areas on day 1 post-laser
and peaked on day 7. Similarly, after the laser injury intensity
of AdipoR1 and Tcad staining in the area of injury increased
gradually from day 1 and peaked on day 5 compared to the
controls (Figs. 1 and S1). Intensity of AdipoR2 staining also
increased from day 1 to day 5 compared to the controls (Figs.
1 and S1). So, all known APN receptors were increased during
the development of CNV.
3.2. Eﬀect of APN on CNV complex size
In intravitreal rAPN injected mice, we observed a 68% de-
crease in CNV size compared to control mice (Fig. 2A) and
a 78 % decrease in the CNV complex size in mice injected intra-
peritoneally (i.p.) with rAPN compared to controls (Fig. 2B).
The values in each group were averaged from 90 laser spots.
The confocal images showed inhibition of CNV in intravitreal
injected animals (Fig. 3C) compared to controls (Fig. 3A and
B). Similarly, i.p. APN injection showed inhibition of CNV
(Fig. 3F) compared to controls (Fig. 3D and E).
3.3. Eﬀect of APN peptide on CNV size
A signiﬁcant inhibition (P < 0.005) in the CNV size in APN
peptide treated mice compared to controls was observed in ani-
mals injected intravitreally (66% inhibition) (Fig. S2A). Simi-
larly, a signiﬁcant inhibition (P < 0.005) in the CNV size in
APN peptide treated mice compared to controls was observed
in animals injected i.p. (77% inhibition) (Fig. S2B). The values
in each group were averaged from 90 laser spots.
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Fig. 2. Measurement of CNV size in APN injected mice. APN was
injected intraperitoneally (i.p.) and intravitreally. The control mice
were injected with PBS i.p. or intravitreal. CNV size was measured in
pixels by using Image Pro-Plus software. There was an 68% decrease
(P < 0.005) in CNV size in intravitreally injected mice compared to
controls (control peptide or PBS injected mice), (A) and 78% decrease
in i.p. injected mice, compared to control (PBS injected) mice, (B). The
values in each group were averaged from 90 laser spots.
Fig. 3. Confocal micrograph of the neovascular complex in C57BL/6 mice sho
lasered mice were anesthetized and perfused with 1 ml of PBS containing 5
elastin by using elastin Ab and Cy3-conjugated secondary Ab and were ex
Bruch’s membrane and RPE. Neovascular complexes were signiﬁcantly inhi
APN, (C) compared to controls (A) and (B). Similarly neovascular complex w
intravitreal injection of rAPN, (F) compared to controls (D) and (E).
P.S. Bora et al. / FEBS Letters 581 (2007) 1977–1982 1979The confocal images shown here represent the images used
to calculate the CNV size (Fig. S3A–F, please see supplemen-
tary data). The confocal images showed that the neovascular
complex was signiﬁcantly inhibited in the laser spots of
C57BL/6 mice treated with APN peptide intravitreally
(Fig. S3C) compared to controls (Fig. S3A and B) and i.p. in-
jected mice (Fig. S3F) compared to controls (Fig. S3D and E).
3.4. Expression of growth factors
Animals were sacriﬁced at day 3 post-laser and RPE-choroid
tissues harvested from the enucleated eyes were pooled sepa-
rately to detect the mRNA and protein levels of b-actin and
vascular endothelial growth factor (VEGF). The expression
of VEGF mRNA (Fig. 4A) and protein (Fig. 4B) in the choroi-
dal tissue at day 3 post-laser was signiﬁcantly inhibited in
rAPN or APN peptide treated mice compared to control ani-
mals.4. Discussion
APN structurally belongs to the complement protein C1q
family [17,26–31]. In the present investigation we have studied
the role of APN (30 kDa) in the murine model of laser-induced
CNV. To the best of our knowledge this is the ﬁrst report
describing the role of APN in CNV model.
We have shown that very low levels of APN, AdipoR1,
AdipoR2 and Tcad are expressed in the normal mice choroidalwing the new vessels (green). Laser-induced C57BL/6 mice and control
0 mg/ml ﬂuorescein-labeled dextran. The ﬂat mounts were stained for
amined by confocal microscope. Elastin stained with red in exposed
bited in the laser spots of C57BL/6 mice treated with i.p. injections of
as signiﬁcantly inhibited in the laser spots of C57BL/6 mice treated with
rAPN treated VEGF
βActin
1       2 1       2
Peptide treated VEGF
rAPN treated VEGF
Peptide treated VEGF
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Fig. 4. VEGF mRNA expression in post-laser treated mice. Equal amounts of the total RNA (0.2 lg) were used to detect the mRNA levels of b-actin
and VEGF. The expression of VEGF in post lasered, day 3 (APN treated) was signiﬁcantly decreased lane 1 compared to post-lasered, day 3 (PBS
treated), lane 2. A strong band for b-actin indicated equal amounts of RNA in each lane, Fig. 5A. Western Blots were performed using antibodies
against VEGF. RPE-choroids were collected from the post-laser groups and were homogenized in solubilizing buﬀer. The supernatant was used to
run on SDS–PAGE. As shown in the Fig. 5B protein levels of VEGF were low in post-laser, day 3 (lane 1) in rAPN or APN peptide treated group
compared to control (PBS treated) group, post-laser day 3, lane 2.
1980 P.S. Bora et al. / FEBS Letters 581 (2007) 1977–1982tissue and the expression of these proteins slowly increased
after laser treatment. Since APN is an anti-angiogenic protein
[15–17], low levels of this protein in normal mice may contrib-
ute to the development of CNV after laser treatment. APN
expression was considered to be limited to adipose tissue until
we and other investigators demonstrated that APN is also ex-Fig. 5. Three-dimensional (3D) structure of the peptide. Lowest energy co
possible binding site or sites (two amines in close proximity and lysine side
peptide. Lowest energy conformer of the polypeptide obtained using the SY
proximity and lysine side chain) are marked by circle (B). Three-dimension
polypeptide obtained using the SYBYL program. The possible binding site (val
the control peptide. Lowest energy conformer of the polypeptide obtained usi
sites (D).pressed in the choroidal tissue, iris and ciliary body, cornea
and osteoblasts [32–34]. APN expression in cells like hepato-
cytes, choroid, and skeletal muscle cells can be induced by
an inﬂammatory process [18,19,24,25,35–37] and expected to
have increased expression of APN, adipoR1, adipoR2 and
Tcad in CNV.nformer of the polypeptide obtained using the SYBYL program. The
chain) are marked by circle (A). Diﬀerent view of 3D structure of the
BYL program. The possible binding site or sites (two amines in close
al structure of the control peptide. Lowest energy conformer of the
ine side chain) is marked by circle (C). Diﬀerent view of 3D structure of
ng the SYBYL program. This 3D view does not show any binding site or
P.S. Bora et al. / FEBS Letters 581 (2007) 1977–1982 1981The role of APN as the anti-angiogenic agent has been dem-
onstrated by investigators in the mouse tumor model [16,31].
The anti-angiogenic activity of APN encouraged us to deter-
mine whether APN could inhibit CNV in the mouse model
of wet type AMD or CNV. We have shown that rAPN injec-
tion in the laser treated mice inhibited CNV size by 78% in i.p.
injected and 68% in intravitreal injected mice. Similarly we
have also shown that a peptide generated from the globular re-
gion of APN was very eﬀective in inhibiting the development
of CNV. This peptide was designed in such a way that they
have no sequence homology with C1q. We have shown that
C1q does not play any role in the development or inhibition
of CNV in this model [25]. This APN peptide was injected
i.p. and intravitreally. There was 77% inhibition of CNV in
the i.p. treated group and 66% inhibition in the intravitreal
group. Thus, our data suggested that the APN peptide was
as eﬀective as rAPN in inhibiting the CNV size.
We have determined the 3D structure for both experimental
and control peptides. The 3D structure of the peptide showed
that in one end of the peptide the amines are in close proxim-
ity. Accordingly, this region could be a possible site of interac-
tion of APN and APN receptors and may play an important
role in the inhibition of CNV complex. A hook-like side chain
of lysine could be another possible interaction site of this pep-
tide and its receptors (Fig. 5A and B). The control peptide also
has a hook-like side chain of valine and this may be a possible
interaction site of this control peptide to receptors [7,38,39].
However, the interaction of control peptide did not cause inhi-
bition of CNV complex size (Fig. 5C and D). Taken together
all the information we believe that the amines in close proxim-
ity at one end of the peptide (not present in control peptide)
may be contributing in the inhibition of CNV complex size
(Fig. 5A and B).
We have shown that rAPN injection in the laser treated
mice not only inhibited CNV size but also inhibited the
expression of VEGF. VEGF plays a very important role in
the development of CNV. When a suﬃcient amount of
APN was present in the choroidal tissue, it inhibited angio-
genic factors like VEGF which then inhibited CNV complex
size [19,24,25,37].
Thus, in summary we have shown that APN acts as an anti-
angiogenic protein in the mouse model of laser-induced CNV.
The unique peptide generated from the globular region of
APN is also very eﬀective in inhibiting the development of
CNV in this model. Since rAPN or APN peptide treatment
inhibited VEGF expression, APN or the APN peptide can be
used as an alternative therapy for the treatment of AMD or
other angiogenesis related diseases.
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